Home > Boards > US Listed > Medical - Healthcare > Precision Therapeutics Inc. (AIPT)

I don't disagree that they are expert 3-Card

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
77Port Member Profile
 
Followed By 2
Posts 181
Boards Moderated 0
Alias Born 08/27/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/13/2019 8:46:12 AM
Predictive Oncology Inc. (Formerly Precision Therapeutics) Names Amelia Warner, Pharm.D., RPh, as Interim Chief Operating Off... GlobeNewswire Inc. - 6/12/2019 8:00:00 AM
Precision Therapeutics Announces Corporate Name Change To Predictive Oncology Inc. GlobeNewswire Inc. - 6/11/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/4/2019 4:12:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/4/2019 4:01:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/28/2019 5:45:51 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 5/24/2019 4:10:17 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/24/2019 3:47:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:15:04 PM
Precision Therapeutics’ Helomics Division Selected by AccuGenomics as Preferred Lab Partner for NIIMBL Grant GlobeNewswire Inc. - 5/21/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 4:03:32 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2019 9:02:17 AM
Precision Therapeutics Gains Extension for Nasdaq Compliance GlobeNewswire Inc. - 5/17/2019 9:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/15/2019 4:35:58 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/15/2019 4:07:54 PM
Precision Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire Inc. - 5/15/2019 4:05:00 PM
Precision Therapeutics to Report First Quarter 2019 Financial Results and Provide Company Update on Wednesday, May 15, 2019 GlobeNewswire Inc. - 5/13/2019 1:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 5:17:36 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:56:15 PM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 4/24/2019 4:31:32 PM
Precision Therapeutics’ Subsidiary Helomics and National Alopecia Areata Foundation Sign Services Agreement to Provide Next... GlobeNewswire Inc. - 4/18/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Receive Alberta Innovates Product Dem... GlobeNewswire Inc. - 4/16/2019 8:45:00 AM
Precision Therapeutics’ Subsidiary, Helomics® Corporation, and SpeciCare, Inc. to Study Innovative Personalized Medicine... GlobeNewswire Inc. - 4/11/2019 8:45:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/10/2019 5:16:33 PM
Precision Therapeutics’ Subsidiary Helomics to Collaborate with Viome to Explore the Impact of the Gut Microbiome on Ovaria... GlobeNewswire Inc. - 4/9/2019 8:45:00 AM
77Port   Tuesday, 04/16/19 03:24:04 PM
Re: Full Contact Yoga post# 4053
Post # of 4057 
I don't disagree that they are expert 3-Card Monty players, always hiding the card by keeping it moving. They seem to put all the money back into the science and, over the long run, that's not a bad thing. But if you're an investor wanting a payout, it sucks.

Today's release had this paragraph and, if it happens as they hope, this technique may be a player in the world of cancer treatment.
Precision Therapeutics’ Subsidiary TumorGenesis and its Partner 48Hour Discovery Inc. Today : Tuesday 16 April 2019

“The TumorGenesis platform and its methodology for tagging a tumor’s diverse cancer cell population is highly complementary to our Helomics discovery service business, which utilizes AI (Artificial Intelligence) and tumor genetic and drug response profiling. Our vision is to tag every patient’s complex tumor cell populations first with biomarkers, then to separate cancer cells using those biomarkers, creating a unique ‘fingerprint’ of that tumor to deliver a personalized medicine approach to cancer diagnosis and treatment,” said Dr. Carl Schwartz, CEO of Precision Therapeutics, Inc.


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist